Hence, a total of 90 patients from nine centers were randomly assigned to one of two study arms for the phase II clinical trial: the first
taking capsules of
olaparib (400 mg twice daily) and the other
taking a combination of the two drugs (200 mg
olaparib in capsule - form twice daily and 30 mg tablets of cediranib once daily).